HUS1900005I1 - Javított nanotestek (TM) aggregáció közvetítette rendellenességek kezelésére - Google Patents
Javított nanotestek (TM) aggregáció közvetítette rendellenességek kezeléséreInfo
- Publication number
- HUS1900005I1 HUS1900005I1 HUS1900005C HUS1900005C HUS1900005I1 HU S1900005 I1 HUS1900005 I1 HU S1900005I1 HU S1900005 C HUS1900005 C HU S1900005C HU S1900005 C HUS1900005 C HU S1900005C HU S1900005 I1 HUS1900005 I1 HU S1900005I1
- Authority
- HU
- Hungary
- Prior art keywords
- aggregation
- treatment
- mediated disorders
- improved nanobodies
- nanobodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68347405P | 2005-05-20 | 2005-05-20 | |
EP12151893.0A EP2444424B1 (en) | 2005-05-20 | 2006-05-19 | Improved nanobodies tm for the treatment of aggregation-mediated disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HUS1900005I1 true HUS1900005I1 (hu) | 2019-03-28 |
Family
ID=37431613
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE12151893A HUE039846T2 (hu) | 2005-05-20 | 2006-05-19 | Javított nanotestek (TM) aggregáció közvetítette rendellenességek kezelésére |
HUS1900005C HUS1900005I1 (hu) | 2005-05-20 | 2019-02-11 | Javított nanotestek (TM) aggregáció közvetítette rendellenességek kezelésére |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE12151893A HUE039846T2 (hu) | 2005-05-20 | 2006-05-19 | Javított nanotestek (TM) aggregáció közvetítette rendellenességek kezelésére |
Country Status (27)
Country | Link |
---|---|
US (3) | US7807162B2 (hu) |
EP (4) | EP2444424B1 (hu) |
JP (1) | JP4986997B2 (hu) |
KR (1) | KR101414438B1 (hu) |
CN (1) | CN101213214B (hu) |
AU (1) | AU2006249090B2 (hu) |
BR (1) | BRPI0609797B8 (hu) |
CA (2) | CA2960105A1 (hu) |
CY (2) | CY1122579T1 (hu) |
DK (1) | DK2444424T3 (hu) |
ES (2) | ES2852423T3 (hu) |
FR (1) | FR19C1005I2 (hu) |
HU (2) | HUE039846T2 (hu) |
IL (2) | IL187168A (hu) |
LT (2) | LT2444424T (hu) |
LU (1) | LUC00099I2 (hu) |
MX (1) | MX2007014564A (hu) |
NL (1) | NL300966I2 (hu) |
NO (3) | NO20076475L (hu) |
NZ (1) | NZ563392A (hu) |
PL (2) | PL3415535T3 (hu) |
PT (2) | PT3415535T (hu) |
RU (1) | RU2433139C2 (hu) |
SI (1) | SI2444424T1 (hu) |
TR (1) | TR201815552T4 (hu) |
WO (1) | WO2006122825A2 (hu) |
ZA (1) | ZA200709570B (hu) |
Families Citing this family (227)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004015425A1 (en) | 2002-08-07 | 2004-02-19 | Umc Utrecht Holding B.V. | Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
NZ540771A (en) | 2003-01-10 | 2009-05-31 | Ablynx Nv | Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen |
HUE034335T2 (hu) | 2004-07-22 | 2018-02-28 | Kingdon Craig R | Kötõmolekulák |
PL1836500T3 (pl) * | 2005-01-14 | 2010-12-31 | Ablynx Nv | Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi |
EP2444424B1 (en) | 2005-05-20 | 2018-08-08 | Ablynx N.V. | Improved nanobodies tm for the treatment of aggregation-mediated disorders |
WO2008049881A2 (en) * | 2006-10-25 | 2008-05-02 | Umc Utrecht Holding Bv | Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases |
WO2008049897A1 (en) * | 2006-10-27 | 2008-05-02 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
AU2007336242B2 (en) | 2006-12-19 | 2012-08-30 | Ablynx N.V. | Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
CA2672965C (en) | 2006-12-19 | 2018-02-06 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
WO2012130874A1 (en) * | 2011-03-28 | 2012-10-04 | Ablynx Nv | Bispecific anti-cxcr7 immunoglobulin single variable domains |
US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
AU2008219216A1 (en) * | 2007-02-21 | 2008-08-28 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
NZ581097A (en) * | 2007-05-24 | 2012-03-30 | Ablynx Nv | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
EP2173772A2 (en) | 2007-07-03 | 2010-04-14 | Ablynx N.V. | Providing improved immunoglobulin sequences by mutating cdr and/or fr positions |
WO2009068628A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Constructs comprising single variable domains and an fc portion derived from lge. |
JP5373823B2 (ja) * | 2008-01-29 | 2013-12-18 | アブリンクス エン.ヴェー. | タンパク質及びポリペプチドを安定化する方法 |
AU2009221106A1 (en) * | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
CN101977654A (zh) * | 2008-03-21 | 2011-02-16 | 埃博灵克斯股份有限公司 | 冯威勒布兰特因子特异性结合物及其应用方法 |
EP2947097A1 (en) | 2008-04-07 | 2015-11-25 | Ablynx N.V. | Amino acid sequences directed against the Notch pathways and uses thereof |
JP2011516603A (ja) | 2008-04-17 | 2011-05-26 | アブリンクス エン.ヴェー. | 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド |
GB2461546B (en) * | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
AU2009273251B2 (en) | 2008-07-22 | 2014-12-18 | Ablynx Nv | Amino acid sequences directed against multitarget scavenger receptors and polypeptides |
EP2387583B1 (en) * | 2009-01-14 | 2018-09-19 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
WO2010100135A1 (en) | 2009-03-05 | 2010-09-10 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
GB0905023D0 (en) * | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
PT2424889E (pt) | 2009-04-30 | 2015-11-12 | Ablynx Nv | Método de produção de anticorpos de domínio |
HUE051430T2 (hu) | 2009-07-10 | 2021-03-01 | Ablynx Nv | Eljárás variábilis domének elõállítására |
PL2473528T3 (pl) | 2009-09-03 | 2015-05-29 | Ablynx Nv | Stabilne formulacje polipeptydów i ich zastosowanie |
UY32920A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
US20120321640A1 (en) | 2009-12-01 | 2012-12-20 | Ablynx N.V. | Von willebrand factor specific binding agents and uses thereof |
EP3309176A1 (en) | 2009-12-14 | 2018-04-18 | Ablynx N.V. | Immunoglobulin single variable domain antibodies against ox40l, constructs and therapeutic use |
WO2011083140A1 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Immunoglobulin single variable domain directed against human cxcr4 |
EP2531523A1 (en) | 2010-02-05 | 2012-12-12 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
WO2011098518A2 (en) | 2010-02-11 | 2011-08-18 | Ablynx Nv | Delivery of immunoglobulin variable domains and constructs thereof |
PT2533761T (pt) | 2010-02-11 | 2019-06-17 | Ablynx Nv | Métodos e composições para a preparação de aerossóis |
EA201201227A1 (ru) * | 2010-03-03 | 2013-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Бипаратопные а-бета-связывающие полипептиды |
WO2011117423A1 (en) | 2010-03-26 | 2011-09-29 | Ablynx N.V. | Immunoglobulin single variable domains directed against cxcr7 |
US9556273B2 (en) | 2010-03-29 | 2017-01-31 | Vib Vzw | Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages |
US9101674B2 (en) | 2010-03-29 | 2015-08-11 | Vib Vzw | Targeting and in vivo imaging of tumor-associated macrophages |
WO2013174537A1 (en) | 2012-05-24 | 2013-11-28 | Vib Vzw | Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages |
MX2012013490A (es) | 2010-05-20 | 2013-01-29 | Ablynx Nv | Materiales biologicos relacionados con her3. |
WO2011161263A1 (en) | 2010-06-25 | 2011-12-29 | Ablynx Nv | Pharmaceutical compositions for cutaneous administration |
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
ES2660895T3 (es) | 2010-10-29 | 2018-03-26 | Ablynx N.V. | Método para la producción de dominios variables individuales de inmunoglobulina |
EP2638068B1 (en) | 2010-11-08 | 2018-12-26 | Novartis AG | Cxcr2 binding polypeptides |
WO2012130872A1 (en) | 2011-03-28 | 2012-10-04 | Ablynx Nv | Method for producing solid formulations comprising immunoglobulin single variable domains |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
US9534039B2 (en) | 2011-05-09 | 2017-01-03 | Ablynx N.V. | Method for the production of immunoglobulin single variable domains |
KR102072250B1 (ko) * | 2011-05-27 | 2020-03-02 | 아블린쓰 엔.브이. | Rankl 결합 펩티드를 이용한 골 재흡수 억제 |
EP4350345A3 (en) | 2011-06-23 | 2024-07-24 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
EP3363812A1 (en) | 2011-06-23 | 2018-08-22 | Ablynx NV | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
US20180009888A9 (en) * | 2011-06-23 | 2018-01-11 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
WO2012175740A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Immunoglobulin single variable domains directed against ige |
CN103917557B (zh) * | 2011-08-17 | 2018-03-20 | 葛兰素集团有限公司 | 具有降低的与抗药物抗体结合的经修饰的单可变结构域抗体 |
WO2013036130A1 (en) | 2011-09-09 | 2013-03-14 | Universiteit Utrecht Holding B.V. | Broadly neutralizing vhh against hiv-1 |
DK2747782T3 (en) | 2011-09-23 | 2018-04-23 | Ablynx Nv | Long-term inhibition of interleukin-6-mediated signal transmission |
DE102011121238A1 (de) | 2011-12-14 | 2013-06-20 | Universitätsklinikum Hamburg-Eppendorf | Einzeldomänen-antikörper gegen clostridium difficile toxine |
DE102011121237A1 (de) | 2011-12-14 | 2013-06-20 | Universitätsklinikum Hamburg-Eppendorf | Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
CA2875703A1 (en) * | 2012-06-08 | 2013-12-12 | Glenmark Pharmaceuticals S.A. | Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof |
WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
WO2017004144A1 (en) | 2015-07-01 | 2017-01-05 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
CA2899693C (en) | 2013-01-30 | 2023-03-14 | Vib Vzw | Novel chimeric polypeptides for screening and drug discovery purposes |
CA2900147C (en) | 2013-02-05 | 2023-09-05 | Vib Vzw | Muscarinic acetylcholine receptor binding agents and uses thereof |
WO2014141192A1 (en) | 2013-03-15 | 2014-09-18 | Erasmus University Medical Center | Generation of heavy chain-only antibodies |
US9617339B2 (en) | 2013-03-15 | 2017-04-11 | Vib Vzw | Method of imaging a cardiovascular disease with an anti-macrophage mannose receptor immunoglobulin single variable domain |
NL1040254C2 (en) * | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
ES2753419T3 (es) | 2013-06-07 | 2020-04-08 | Univ Duke | Inhibidores del factor H del complemento |
WO2014201400A2 (en) * | 2013-06-13 | 2014-12-18 | Biogen Idec Ma Inc. | Anti-factor viii antibodies or uses thereof |
WO2015121092A1 (en) | 2014-01-30 | 2015-08-20 | Vib Vzw | Opioid receptor binding agents and uses thereof |
US10544231B2 (en) * | 2014-04-16 | 2020-01-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the prevention or the treatment of bleeding episodes |
DK3143403T3 (da) | 2014-05-16 | 2022-01-17 | Ablynx Nv | Fremgangsmåder til påvisning og/eller måling af anti-lægemiddelantistoffer, især behandlingsinducerede anti-lægemiddelantistoffer |
AU2015261536B2 (en) | 2014-05-16 | 2020-05-07 | Ablynx Nv | Improved immunoglobulin variable domains |
NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
US10641779B2 (en) | 2014-07-22 | 2020-05-05 | Vib Vzw | Methods to select for agents that stabilize protein complexes |
WO2016057398A1 (en) | 2014-10-07 | 2016-04-14 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
MA41097A (fr) * | 2014-12-05 | 2017-10-10 | Glenmark Pharmaceuticals Sa | Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses |
ES2772348T3 (es) | 2014-12-19 | 2020-07-07 | Ablynx Nv | Dímeros de Nanobody con uniones cisteína |
JP6929786B2 (ja) | 2015-04-02 | 2021-09-01 | アブリンクス エン.ヴェー. | 強力な抗hiv活性を有する二重特異性cxcr4−cd4ポリペプチド |
CA2981543A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
CN107847559B (zh) | 2015-05-13 | 2022-07-01 | 埃博灵克斯股份有限公司 | 基于cd3反应性的t细胞募集多肽 |
SI3294768T1 (sl) | 2015-05-13 | 2019-11-29 | Ablynx Nv | Polipeptidi, ki rekrutirajo celice T, na osnovi reaktivnosti TCR alfa/beta |
WO2016186994A1 (en) * | 2015-05-15 | 2016-11-24 | Children's Medical Center Corporation | Methods relating to the diagnosis and treatment of thrombotic microangiopathy |
CN111234027A (zh) | 2015-05-21 | 2020-06-05 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
CA2991637C (en) | 2015-07-31 | 2022-07-05 | Medimmune Limited | Methods for treating hepcidin-mediated disorders |
NO2768984T3 (hu) | 2015-11-12 | 2018-06-09 | ||
WO2017080850A1 (en) | 2015-11-13 | 2017-05-18 | Ablynx Nv | Improved serum albumin-binding immunoglobulin variable domains |
JP6779997B2 (ja) * | 2015-11-18 | 2020-11-04 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Pd1/ctla4結合性物質 |
CN114605530A (zh) | 2015-11-18 | 2022-06-10 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合剂 |
EP3377527A1 (en) * | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme Corp. | Ctla4 binders |
EP3932945A1 (en) | 2015-11-27 | 2022-01-05 | Ablynx NV | Polypeptides inhibiting cd40l |
WO2017129630A1 (en) * | 2016-01-26 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-vwf d'd3 single-domain antibodies and polypeptides comprising thereof |
AU2017259876A1 (en) | 2016-05-02 | 2018-10-25 | Ablynx Nv | Treatment of RSV infection |
CN109153729A (zh) * | 2016-05-13 | 2019-01-04 | 免疫医疗有限责任公司 | Cd40l-fc融合多肽及其使用方法 |
EA201892693A1 (ru) | 2016-05-20 | 2019-04-30 | Харпун Терапьютикс, Инк. | Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3 |
JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス,インク. | 単一ドメイン血清アルブミン結合タンパク質 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
CN109313183B (zh) | 2016-06-23 | 2022-10-21 | 埃博灵克斯股份有限公司 | 免疫球蛋白单可变结构域的改进的药代动力学测定 |
WO2018007442A1 (en) | 2016-07-06 | 2018-01-11 | Ablynx N.V. | Treatment of il-6r related diseases |
WO2018029182A1 (en) | 2016-08-08 | 2018-02-15 | Ablynx N.V. | Il-6r single variable domain antibodies for treatment of il-6r related diseases |
US11098113B2 (en) | 2016-09-15 | 2021-08-24 | Vib Vzw | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
KR20240076829A (ko) | 2016-11-16 | 2024-05-30 | 아블린쓰 엔.브이. | Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드 |
CA3044729A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Psma targeting trispecific proteins and methods of use |
JP6812551B2 (ja) | 2016-11-23 | 2021-01-13 | ハープーン セラピューティクス,インク. | 前立腺特異的膜抗原結合タンパク質 |
WO2018099968A1 (en) | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Treatment of infection by respiratory syncytial virus (rsv) |
KR20240001271A (ko) | 2016-12-07 | 2024-01-03 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인 |
EP3571224B1 (en) | 2017-01-17 | 2024-08-07 | Ablynx NV | Improved serum albumin binders |
US11414481B2 (en) | 2017-01-17 | 2022-08-16 | Ablynx N.V. | Serum albumin binders |
CA3051865C (en) | 2017-02-01 | 2023-01-17 | Yale University | Treatment of diuretic resistance |
JP7186401B2 (ja) | 2017-02-28 | 2022-12-09 | フエー・イー・ベー・フエー・ゼツト・ウエー | タンパク質の経口送達のための手段及び方法 |
WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
MX2019011702A (es) | 2017-03-31 | 2019-11-01 | Ablynx Nv | Ensayos de inmunogenicidad mejorados. |
US10865238B1 (en) * | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
JP2020519261A (ja) | 2017-05-11 | 2020-07-02 | ブイアイビー ブイゼットダブリュVib Vzw | 可変免疫グロブリンドメインのグリコシル化 |
KR20200026810A (ko) | 2017-05-12 | 2020-03-11 | 하푼 테라퓨틱스, 인크. | Msln 표적화 삼중 특이적 단백질 및 사용 방법 |
IL300964A (en) | 2017-05-12 | 2023-04-01 | Harpoon Therapeutics Inc | mesothelin binding proteins |
TW202413408A (zh) * | 2017-06-02 | 2024-04-01 | 比利時商艾伯林克斯公司 | 結合聚集蛋白聚糖之免疫球蛋白 |
MX2019014397A (es) | 2017-06-02 | 2020-02-10 | Merck Patent Gmbh | Polipeptidos que enlazan adamts5, mmp13 y agrecano. |
JP2020521804A (ja) | 2017-06-02 | 2020-07-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Mmp13結合免疫グロブリン |
CN111032695B (zh) | 2017-06-02 | 2024-06-25 | 默克专利股份有限公司 | 结合adamts的免疫球蛋白 |
CN111108126B (zh) | 2017-07-19 | 2024-04-26 | 非营利性组织佛兰芒综合大学生物技术研究所 | 血清白蛋白结合剂 |
PE20201183A1 (es) | 2017-10-13 | 2020-11-03 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso |
EA202090739A1 (ru) | 2017-10-13 | 2020-09-07 | Харпун Терапьютикс, Инк. | Белки, связывающие антиген созревания в-клеток |
WO2019086548A1 (en) | 2017-10-31 | 2019-05-09 | Vib Vzw | Novel antigen-binding chimeric proteins and methods and uses thereof |
US20200199206A1 (en) * | 2017-12-08 | 2020-06-25 | AC Thera, LLC | Bacterial toxin-neutralizing nanobodies and methods of making and using the same |
BR112020013519A2 (pt) | 2018-01-05 | 2020-12-01 | Corvidia Therapeutics, Inc | método para tratamento de uma inflamação. |
CN112004826B (zh) | 2018-02-05 | 2024-06-14 | 自由大学基金会 | 反向激动性抗us28抗体 |
CN111670202A (zh) | 2018-02-06 | 2020-09-15 | 埃博灵克斯股份有限公司 | 以免疫球蛋白单可变结构域治疗ttp初次发作的方法 |
WO2019155041A1 (en) | 2018-02-12 | 2019-08-15 | Vib Vzw | Gβγ COMPLEX ANTIBODIES AND USES THEREOF |
WO2019156566A1 (en) | 2018-02-12 | 2019-08-15 | Umc Utrecht Holding B.V. | Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain |
CN111655296A (zh) | 2018-02-26 | 2020-09-11 | 埃博灵克斯股份有限公司 | 编码肽接头的经改良核苷酸序列 |
WO2019166622A1 (en) | 2018-03-01 | 2019-09-06 | Vrije Universiteit Brussel | Human pd-l1-binding immunoglobulins |
JP2021519093A (ja) | 2018-03-27 | 2021-08-10 | ユーエムシー ユトレヒト ホールディング ビー.ブイ. | 微小血管血栓症の処置のための標的化血栓溶解 |
WO2019226050A2 (en) | 2018-05-24 | 2019-11-28 | Wageningen Universiteit | Novel viral anti-infective reagents |
KR102101561B1 (ko) * | 2018-07-25 | 2020-04-20 | 가톨릭대학교 산학협력단 | 신생혈관 표적용 조영제 조성물 및 이의 제조방법 |
BR112021005769A2 (pt) | 2018-09-25 | 2021-07-06 | Harpoon Therapeutics Inc | proteínas de ligação a dll3 e métodos de uso |
EP3636657A1 (en) | 2018-10-08 | 2020-04-15 | Ablynx N.V. | Chromatography-free antibody purification method |
WO2020080941A1 (en) | 2018-10-16 | 2020-04-23 | Umc Utrecht Holding B.V. | Anti- low-density lipoprotein receptor-related protein 5/6 antibodies |
WO2020130838A2 (en) | 2018-12-21 | 2020-06-25 | Qvq Holding B.V. | Antibodies for preventing or treating candidiasis |
GB201901608D0 (en) | 2019-02-06 | 2019-03-27 | Vib Vzw | Vaccine adjuvant conjugates |
EP3715374A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
WO2020204714A1 (en) | 2019-04-02 | 2020-10-08 | Immunetune B.V. | Immune-stimulatory compositions and use thereof |
SG11202111980QA (en) | 2019-04-29 | 2021-11-29 | Confo Therapeutics N V | Screening methods and assays for use with transmembrane proteins, in particular with gpcrs |
WO2020221888A1 (en) | 2019-04-30 | 2020-11-05 | Vib Vzw | Cystic fibrosis transmembrane conductance regulator stabilizing agents |
MA55809A (fr) | 2019-05-01 | 2022-03-09 | Novo Nordisk As | Formulation d'anticorps anti-il-6 |
US20220228116A1 (en) | 2019-05-28 | 2022-07-21 | Vib Vzw | Cd8+ t-cells lacking plexins and their application in cancer treatment |
WO2020239945A1 (en) | 2019-05-28 | 2020-12-03 | Vib Vzw | Cancer treatment by targeting plexins in the immune compartment |
WO2021025556A1 (en) | 2019-08-05 | 2021-02-11 | Stichting Vu | Identification and elimination of hcmv-infected cells |
WO2021039574A1 (ja) * | 2019-08-23 | 2021-03-04 | 株式会社カネカ | O結合型糖鎖修飾が抑制された重鎖抗体 |
EP3799881A1 (en) | 2019-10-04 | 2021-04-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Single domain antibodies specifically binding globo - series glycans |
US20220380456A1 (en) | 2019-10-21 | 2022-12-01 | Vib Vzw | Nanodisc-specific antigen-binding chimeric proteins |
CA3160506A1 (en) | 2019-11-11 | 2021-05-20 | Ibi-Ag Innovative Bio Insecticides Ltd. | Insect control nanobodies and uses thereof |
WO2021105438A1 (en) | 2019-11-27 | 2021-06-03 | Vib Vzw | Positive allosteric modulators of the calcium-sensing receptor |
GB201918279D0 (en) | 2019-12-12 | 2020-01-29 | Vib Vzw | Glycosylated single chain immunoglobulin domains |
EP4077372A1 (en) | 2019-12-20 | 2022-10-26 | Vib Vzw | Nanobody exchange chromatography |
WO2021140205A1 (en) | 2020-01-10 | 2021-07-15 | Confo Therapeutics N.V. | Methods for generating antibodies and antibody fragments and libraries comprising same |
WO2021156490A2 (en) | 2020-02-06 | 2021-08-12 | Vib Vzw | Corona virus binders |
IL295448A (en) | 2020-02-21 | 2022-10-01 | Harpoon Therapeutics Inc | flt3 binding proteins and methods of use |
WO2021170540A1 (en) | 2020-02-25 | 2021-09-02 | Vib Vzw | Leucine-rich repeat kinase 2 allosteric modulators |
US20230279115A1 (en) | 2020-04-22 | 2023-09-07 | Mabwell (shanghai) Bioscience Co., Ltd. | Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof |
WO2021229104A1 (en) | 2020-05-15 | 2021-11-18 | Université de Liège | Anti-cd38 single-domain antibodies in disease monitoring and treatment |
EP4172214A1 (en) * | 2020-06-26 | 2023-05-03 | Monash University | Anti-vwf antibodies and uses thereof |
WO2022003156A1 (en) | 2020-07-02 | 2022-01-06 | Oncurious Nv | Ccr8 non-blocking binders |
AR122933A1 (es) | 2020-07-10 | 2022-10-19 | Novo Nordisk As | Métodos para tratar la enfermedad cardiovascular |
CA3196737A1 (en) | 2020-09-24 | 2022-03-31 | Massimiliano Mazzone | Combination of p2y6 inhibitors and immune checkpoint inhibitors |
WO2022063957A1 (en) | 2020-09-24 | 2022-03-31 | Vib Vzw | Biomarker for anti-tumor therapy |
EP4217390A1 (en) | 2020-09-25 | 2023-08-02 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l |
JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるltbrアゴニスト |
WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
WO2022133050A1 (en) * | 2020-12-18 | 2022-06-23 | Bioardis, Llc | Gpc3 binding molecules and uses thereof |
KR20230126714A (ko) * | 2020-12-18 | 2023-08-30 | 바이오아르디스 엘엘씨 | 메소텔린 결합 분자 및 이의 사용 |
AU2021401296A1 (en) * | 2020-12-18 | 2023-07-13 | Bioardis, Llc | Epcam binding molecules and uses thereof |
AU2021400975A1 (en) * | 2020-12-18 | 2023-07-13 | Bioardis, Llc | Cea6 binding molecules and uses thereof |
US11897951B2 (en) | 2020-12-18 | 2024-02-13 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α |
WO2022136693A1 (en) * | 2020-12-23 | 2022-06-30 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
GB202020502D0 (en) | 2020-12-23 | 2021-02-03 | Vib Vzw | Antibody composistion for treatment of corona virus infection |
US20240052045A1 (en) | 2020-12-24 | 2024-02-15 | Vib Vzw | Murine cross-reactive human ccr8 binders |
WO2022136647A1 (en) | 2020-12-24 | 2022-06-30 | Oncurious Nv | Human ccr8 binders |
EP4267618A1 (en) | 2020-12-24 | 2023-11-01 | Vib Vzw | Non-blocking human ccr8 binders |
CA3207548A1 (en) | 2021-02-05 | 2022-08-11 | Xavier Saelens | Sarbecovirus binders |
CN117794566A (zh) | 2021-02-05 | 2024-03-29 | Vib研究所 | 沙贝病毒结合剂 |
EP4294407A1 (en) | 2021-02-17 | 2023-12-27 | Vib Vzw | Inhibition of slc4a4 in the treatment of cancer |
CA3211270A1 (en) | 2021-02-19 | 2022-08-25 | Vib Vzw | Cation-independent mannose-6-phosphate receptor binders |
WO2022199804A1 (en) | 2021-03-24 | 2022-09-29 | Vib Vzw | Nek6 inhibition to treat als and ftd |
WO2022216157A1 (en) | 2021-04-09 | 2022-10-13 | Stichting Radboud Universiteit | Off the shelf proximity biotinylation enzyme |
US20240261446A1 (en) | 2021-05-17 | 2024-08-08 | Université de Liège | Anti-cd38 single domain antibodies in disease monitoring and treatment |
WO2022258606A1 (en) | 2021-06-07 | 2022-12-15 | Gadeta B.V. | Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response |
EP4359421A1 (en) | 2021-06-23 | 2024-05-01 | Vib Vzw | Means and methods for selection of specific binders |
EP4365199A1 (en) | 2021-06-29 | 2024-05-08 | Shandong Simcere Biopharmaceutical Co., Ltd. | Cd16 antibody and use thereof |
WO2023288217A2 (en) * | 2021-07-12 | 2023-01-19 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Methods and sytems for nanobody humanization |
WO2023006040A1 (zh) | 2021-07-30 | 2023-02-02 | 江苏先声药业有限公司 | 抗pvrig/抗tigit双特异性抗体和应用 |
WO2023016828A2 (en) | 2021-07-30 | 2023-02-16 | Vib Vzw | Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation |
EP4381094A1 (en) | 2021-08-03 | 2024-06-12 | Wageningen Universiteit | Argonaute-based nucleic acid detection system |
WO2023098846A1 (zh) | 2021-12-03 | 2023-06-08 | 江苏先声药业有限公司 | 抗bcma纳米抗体及其应用 |
AU2022409733A1 (en) | 2021-12-17 | 2024-08-01 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123 |
WO2023125888A1 (zh) | 2021-12-31 | 2023-07-06 | 山东先声生物制药有限公司 | 一种gprc5d抗体及其应用 |
WO2023135198A1 (en) | 2022-01-12 | 2023-07-20 | Vib Vzw | Human ntcp binders for therapeutic use and liver-specific targeted delivery |
WO2023148397A1 (en) | 2022-02-07 | 2023-08-10 | Vib Vzw | Engineered stabilizing aglycosylated fc-regions |
WO2023198848A1 (en) | 2022-04-13 | 2023-10-19 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
WO2023222825A1 (en) | 2022-05-18 | 2023-11-23 | Vib Vzw | Sarbecovirus spike s2 subunit binders |
WO2023227594A1 (en) | 2022-05-24 | 2023-11-30 | Gadeta Bv | Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof |
WO2023237541A1 (en) | 2022-06-07 | 2023-12-14 | Gadeta B.V. | Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response |
WO2024003873A1 (en) | 2022-06-30 | 2024-01-04 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Single variable domain antibodies against tumor necrosis factor-alpha |
WO2024008755A1 (en) | 2022-07-04 | 2024-01-11 | Vib Vzw | Blood-cerebrospinal fluid barrier crossing antibodies |
US20240075068A1 (en) | 2022-07-15 | 2024-03-07 | Gadeta B.V. | Novel soluble gamma T-cell (or soluble delta T-cell) receptor chains (or soluble gammadelta T-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response |
US20240132624A1 (en) | 2022-07-27 | 2024-04-25 | Ablynx N.V. | Polypeptides binding to a specific epitope of the neonatal fc receptor |
WO2024068744A1 (en) | 2022-09-27 | 2024-04-04 | Vib Vzw | Antivirals against human parainfluenza virus |
WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
WO2024096735A1 (en) | 2022-10-31 | 2024-05-10 | Stichting Amsterdam UMC | Single domain anti-cd169 antibodies |
WO2024101989A1 (en) | 2022-11-08 | 2024-05-16 | Stichting Amsterdam UMC | Activation inducible antigen receptors for adoptive immunotherapy |
WO2024105091A1 (en) | 2022-11-15 | 2024-05-23 | Imec Vzw | Method and system for droplet manipulation |
WO2024126805A1 (en) | 2022-12-15 | 2024-06-20 | Aarhus Universitet | Synthetic activation of multimeric transmembrane receptors |
WO2024126685A1 (en) * | 2022-12-15 | 2024-06-20 | Institut National de la Santé et de la Recherche Médicale | Single-domain antibody targeting von wilebrand factor a3-domain |
WO2024133301A1 (en) | 2022-12-19 | 2024-06-27 | Umc Utrecht Holding B.V. | Btn2a1 binding peptide |
WO2024133935A1 (en) | 2022-12-23 | 2024-06-27 | Ablynx Nv | Protein-based conjugation carriers |
WO2024156888A1 (en) | 2023-01-27 | 2024-08-02 | Vib Vzw | Cd163-binding conjugates |
WO2024156881A1 (en) | 2023-01-27 | 2024-08-02 | Vib Vzw | CD8b-BINDING POLYPEPTIDES |
WO2024165710A1 (en) | 2023-02-09 | 2024-08-15 | Seni-Preps B.V. | Immunoglobulin single variable domains that inhibit urease and use thereof |
WO2024170756A1 (en) | 2023-02-17 | 2024-08-22 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
WO2024175787A1 (en) | 2023-02-24 | 2024-08-29 | Vrije Universiteit Brussel | Anti-inflammatory pannexin 1 channel inhibitors |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
US5238919A (en) | 1986-05-30 | 1993-08-24 | Scipps Clinic And Research Foundation | Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor |
ATE122238T1 (de) | 1987-06-10 | 1995-05-15 | Dana Farber Cancer Inst Inc | Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen. |
US5200510A (en) | 1987-06-16 | 1993-04-06 | Zymogenetics, Inc. | Method for purifying factor viii:c, von willebrand factor and complexes thereof |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US5770198A (en) | 1988-05-18 | 1998-06-23 | The Research Foundation Of The State Of New York | Platelet-specific chimeric 7E3 immunoglobulin |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
GB8905400D0 (en) | 1989-03-09 | 1989-04-19 | Jonker Margreet | Medicaments |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
AU664561B2 (en) | 1991-06-21 | 1995-11-23 | University Of Cincinnati, The | Orally administrable therapeutic proteins and method of making |
JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
CA2122732C (en) | 1991-11-25 | 2008-04-08 | Marc D. Whitlow | Multivalent antigen-binding proteins |
DE69334095T2 (de) | 1992-07-17 | 2007-04-12 | Dana-Farber Cancer Institute, Boston | Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen |
PT656946E (pt) | 1992-08-21 | 2001-12-28 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
SG55079A1 (en) | 1992-12-11 | 1998-12-21 | Dow Chemical Co | Multivalent single chain antibodies |
AU6268894A (en) | 1993-02-22 | 1994-09-14 | Alza Corporation | Compositions for oral delivery of active agents |
DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
GB9311454D0 (en) | 1993-06-03 | 1993-07-21 | Agricultural & Food Res | Pharmaceutical compositions |
DE69434447T2 (de) | 1993-06-07 | 2006-05-18 | Vical, Inc., San Diego | Für die gentherapie verwendbare plasmide |
DE69426527T2 (de) | 1993-06-09 | 2001-08-30 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno, Delft | Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen |
FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
US6091639A (en) | 1993-08-27 | 2000-07-18 | Kabushiki Kaisha Toshiba | Non-volatile semiconductor memory device and data programming method |
DE69435112D1 (de) | 1993-09-10 | 2008-08-21 | Univ Columbia | Verwendung von grünem fluoreszenzprotein |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
JPH10501681A (ja) | 1994-02-22 | 1998-02-17 | ダナ−ファーバー キャンサー インスティチュート | 核酸送達システムならびにその合成および使用方法 |
US5670132A (en) | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
DE69530316T2 (de) | 1994-11-30 | 2004-02-12 | Ajinomoto Co., Inc. | Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper |
WO1996022307A1 (en) | 1995-01-19 | 1996-07-25 | The Research Foundation Of State University Of New York | Genes encoding an insect calcium channel |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US5693492A (en) | 1995-05-05 | 1997-12-02 | Merck & Co., Inc. | DNA encoding glutamate gated chloride channels |
AU723325B2 (en) | 1995-06-23 | 2000-08-24 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
CA2232727C (en) | 1995-09-22 | 2002-03-26 | Novo Nordisk A/S | Novel variants of green fluorescent protein, gfp |
JP2000508892A (ja) | 1996-04-04 | 2000-07-18 | ユニリーバー・ナームローゼ・ベンノートシャープ | 多価および多特異的抗原結合タンパク |
US6027881A (en) | 1996-05-08 | 2000-02-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence |
DE69738166T2 (de) | 1996-06-27 | 2008-06-19 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Antikörpermoleküle, die spezifisch mit dem aktiven Zentrum oder dem aktiven Spalt eines Zielmoleküls interagieren |
US6124128A (en) | 1996-08-16 | 2000-09-26 | The Regents Of The University Of California | Long wavelength engineered fluorescent proteins |
WO1998021355A1 (en) | 1996-11-15 | 1998-05-22 | Life Technologies, Inc. | Mutants of green fluorescent protein |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
WO1999009055A2 (en) | 1997-08-18 | 1999-02-25 | Innogenetics N.V. | Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders |
US5895466A (en) | 1997-08-19 | 1999-04-20 | At&T Corp | Automated natural language understanding customer service system |
WO1999023221A2 (en) | 1997-10-27 | 1999-05-14 | Unilever Plc | Multivalent antigen-binding proteins |
BR9907241A (pt) | 1998-01-26 | 2000-10-17 | Unilever Nv | Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo |
IL137963A0 (en) | 1998-02-19 | 2001-10-31 | Xcyte Teherapies Inc | Compositions and methods for regulating lymphocyte activation |
ATE535154T1 (de) | 1998-03-12 | 2011-12-15 | Vhsquared Ltd | Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben |
CZ121599A3 (cs) | 1998-04-09 | 1999-10-13 | Aventis Pharma Deutschland Gmbh | Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu |
EP0967284A1 (en) | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiesterases |
DE69905291T3 (de) | 1998-07-06 | 2009-06-25 | Perkinelmer Cellular Sciences Belgium Sprl | Bioluminenztest für agonisten oder antagonisten eines kalzium-gekuppelten-rezeptors |
US6228360B1 (en) | 1998-08-19 | 2001-05-08 | Ajinomoto Co., Inc. | Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody |
AU755549B2 (en) | 1998-10-23 | 2002-12-12 | Brigham And Women's Hospital | Conformation-specific anti-von willebrand factor antibodies |
EP1002861A1 (en) | 1998-10-26 | 2000-05-24 | Unilever Plc | Antigen-binding proteins comprising a linker which confers restricted conformational flexibility |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
WO2000040968A1 (en) | 1999-01-05 | 2000-07-13 | Unilever Plc | Binding of antibody fragments to solid supports |
WO2000043507A1 (en) | 1999-01-19 | 2000-07-27 | Unilever Plc | Method for producing antibody fragments |
JP2002535993A (ja) | 1999-02-05 | 2002-10-29 | リイクスニフェルシタイト ライデン | 組換え体細胞における代謝物の生合成を変調する方法 |
US6419934B1 (en) | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | TNF modulators for treating neurological disorders associated with viral infection |
JP4726302B2 (ja) | 1999-03-15 | 2011-07-20 | ユニバーシティ オブ ブリティッシュ コロンビア | Abc1ポリペプチドおよびコレステロール水準を調節する方法と試薬 |
EP1169453A1 (en) | 1999-04-22 | 2002-01-09 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins |
TR200200441T2 (tr) | 1999-06-18 | 2002-11-21 | Cv Therapeutics, Inc. | ATP bağlayıcı kaset transportör protein ABC1' i kullanarak kolesterolün dışa akımını artırmak ve HDL' yi yükseltmek için terkipler ve yöntemler. |
US7622259B1 (en) | 1999-07-05 | 2009-11-24 | K.U. Leuven Research & Development | Detection of von-Willebrand factor (vWF) activity |
AU6322900A (en) | 1999-08-02 | 2001-02-19 | Keygene N.V. | Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method |
GB9922124D0 (en) | 1999-09-17 | 1999-11-17 | Pfizer Ltd | Phosphodiesterase enzymes |
US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
DE19955408A1 (de) | 1999-11-18 | 2001-05-23 | Bayer Ag | GABA-B-Rezeptoren |
WO2001044301A1 (en) | 1999-11-29 | 2001-06-21 | Unilever Plc | Immobilized single domain antigen-binding molecules |
WO2001040310A2 (en) | 1999-11-29 | 2001-06-07 | Unilever Plc | Immobilisation of proteins using a polypeptide segment |
DE60138333D1 (de) | 2000-03-14 | 2009-05-28 | Unilever Nv | Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen |
US20030190598A1 (en) | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
US7943129B2 (en) | 2000-05-26 | 2011-05-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
US6506901B2 (en) | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
US6741957B1 (en) | 2000-07-21 | 2004-05-25 | Daimlerchrysler Corporation | Analytical tire model for vehicle durability and ride comfort analysis |
CA2422881A1 (en) | 2000-10-13 | 2002-04-18 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
US20040053340A1 (en) | 2000-12-13 | 2004-03-18 | De Haard Johannes Joseph | Protein arrays |
GB0031448D0 (en) | 2000-12-22 | 2001-02-07 | Leuven K U Res & Dev | Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation |
US7054297B1 (en) | 2000-12-28 | 2006-05-30 | Cisco Technology, Inc. | Distribution of packets to high data rate communications devices using multicast protocols |
DE10105526B4 (de) | 2001-02-07 | 2004-12-23 | Robert Bosch Gmbh | Verfahren zur Herstellung einer Klappenanordnung |
WO2003014960A2 (en) | 2001-08-03 | 2003-02-20 | Medical Research Council | Method of identifying a consensus sequence for intracellular antibodies |
JP4213586B2 (ja) | 2001-09-13 | 2009-01-21 | 株式会社抗体研究所 | ラクダ抗体ライブラリーの作製方法 |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
KR100599789B1 (ko) | 2001-12-03 | 2006-07-12 | 삼성에스디아이 주식회사 | 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법 |
WO2003050531A2 (en) | 2001-12-11 | 2003-06-19 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
US20050037358A1 (en) | 2001-12-21 | 2005-02-17 | Serge Muyldermans | Method for cloning of variable domain sequences |
CA2471645A1 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
ES2263984T3 (es) | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
US20050136056A1 (en) | 2002-07-29 | 2005-06-23 | Shunsuke Kageyama | Pharmaceutical composition for the treatment of thrombocytopenia |
WO2004015425A1 (en) | 2002-08-07 | 2004-02-19 | Umc Utrecht Holding B.V. | Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha |
US7004940B2 (en) | 2002-10-10 | 2006-02-28 | Ethicon, Inc. | Devices for performing thermal ablation having movable ultrasound transducers |
JP2006512910A (ja) | 2002-10-23 | 2006-04-20 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | A34およびa33様3dna、タンパク質、それらに対する抗体、ならびに同一物を使用した治療方法 |
EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
EP1558650A2 (en) | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders |
NZ540771A (en) | 2003-01-10 | 2009-05-31 | Ablynx Nv | Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen |
CN1845938B (zh) | 2003-06-30 | 2010-05-26 | 杜门蒂斯有限公司 | 多肽 |
DE60334645D1 (de) | 2003-11-07 | 2010-12-02 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
US7180370B2 (en) | 2004-09-01 | 2007-02-20 | Micron Technology, Inc. | CMOS amplifiers with frequency compensating capacitors |
US7566701B2 (en) * | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
AU2005293752A1 (en) * | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease |
PL1836500T3 (pl) | 2005-01-14 | 2010-12-31 | Ablynx Nv | Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi |
EP2444424B1 (en) | 2005-05-20 | 2018-08-08 | Ablynx N.V. | Improved nanobodies tm for the treatment of aggregation-mediated disorders |
WO2008049881A2 (en) | 2006-10-25 | 2008-05-02 | Umc Utrecht Holding Bv | Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases |
CN101977654A (zh) * | 2008-03-21 | 2011-02-16 | 埃博灵克斯股份有限公司 | 冯威勒布兰特因子特异性结合物及其应用方法 |
-
2006
- 2006-05-19 EP EP12151893.0A patent/EP2444424B1/en active Active
- 2006-05-19 RU RU2007147381/10A patent/RU2433139C2/ru active
- 2006-05-19 AU AU2006249090A patent/AU2006249090B2/en active Active
- 2006-05-19 CA CA2960105A patent/CA2960105A1/en not_active Abandoned
- 2006-05-19 BR BRPI0609797A patent/BRPI0609797B8/pt active IP Right Grant
- 2006-05-19 NZ NZ563392A patent/NZ563392A/en unknown
- 2006-05-19 PL PL18186517T patent/PL3415535T3/pl unknown
- 2006-05-19 KR KR1020077029416A patent/KR101414438B1/ko active IP Right Grant
- 2006-05-19 HU HUE12151893A patent/HUE039846T2/hu unknown
- 2006-05-19 ES ES18186517T patent/ES2852423T3/es active Active
- 2006-05-19 CN CN200680024012.1A patent/CN101213214B/zh active Active
- 2006-05-19 PL PL12151893T patent/PL2444424T3/pl unknown
- 2006-05-19 WO PCT/EP2006/004773 patent/WO2006122825A2/en active Application Filing
- 2006-05-19 DK DK12151893.0T patent/DK2444424T3/en active
- 2006-05-19 CA CA2608873A patent/CA2608873C/en not_active Expired - Fee Related
- 2006-05-19 SI SI200632287T patent/SI2444424T1/sl unknown
- 2006-05-19 TR TR2018/15552T patent/TR201815552T4/tr unknown
- 2006-05-19 EP EP18186517.1A patent/EP3415535B1/en active Active
- 2006-05-19 LT LTEP12151893.0T patent/LT2444424T/lt unknown
- 2006-05-19 EP EP06776035A patent/EP2007814A2/en not_active Withdrawn
- 2006-05-19 JP JP2008511652A patent/JP4986997B2/ja active Active
- 2006-05-19 PT PT181865171T patent/PT3415535T/pt unknown
- 2006-05-19 MX MX2007014564A patent/MX2007014564A/es active IP Right Grant
- 2006-05-19 US US11/920,793 patent/US7807162B2/en active Active
- 2006-05-19 EP EP17175833.7A patent/EP3243839A1/en not_active Withdrawn
- 2006-05-19 ES ES12151893T patent/ES2694247T3/es active Active
- 2006-05-19 PT PT12151893T patent/PT2444424T/pt unknown
-
2007
- 2007-11-05 IL IL187168A patent/IL187168A/en active IP Right Grant
- 2007-11-06 ZA ZA200709570A patent/ZA200709570B/xx unknown
- 2007-12-17 NO NO20076475A patent/NO20076475L/no not_active Application Discontinuation
-
2010
- 2010-06-24 US US12/822,729 patent/US8372398B2/en active Active
- 2010-10-11 IL IL208607A patent/IL208607A0/en unknown
-
2013
- 2013-01-04 US US13/734,129 patent/US20130136736A1/en not_active Abandoned
-
2018
- 2018-11-07 CY CY20181101166T patent/CY1122579T1/el unknown
-
2019
- 2019-02-06 LU LU00099C patent/LUC00099I2/fr unknown
- 2019-02-11 NL NL300966C patent/NL300966I2/nl unknown
- 2019-02-11 HU HUS1900005C patent/HUS1900005I1/hu unknown
- 2019-02-13 FR FR19C1005C patent/FR19C1005I2/fr active Active
- 2019-02-14 CY CY2019006C patent/CY2019006I2/el unknown
- 2019-02-20 LT LTPA2019504C patent/LTC2444424I2/lt unknown
- 2019-02-27 NO NO20190279A patent/NO345342B1/no active Protection Beyond IP Right Term
-
2021
- 2021-05-20 NO NO2021020C patent/NO2021020I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1900005I1 (hu) | Javított nanotestek (TM) aggregáció közvetítette rendellenességek kezelésére | |
ZA200806074B (en) | Compounds for the treatment of inflammatory disorders | |
ZA200803440B (en) | Compounds for the treatment of metabolic disorders | |
EP1976377A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
EP1983972A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
IL195203A0 (en) | Compounds for the treatment of metabolic disorders | |
IL195906A0 (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
ZA200805645B (en) | Compounds for the treatment of metabolic disorders | |
ZA200806455B (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
ZA200805159B (en) | Imidazole derivatives for the treatment of gastrointestinal disorders | |
GB0517387D0 (en) | Combinations for the treatment of cancer | |
IL192877A0 (en) | Use of 2-imidazoles for the treatment of cns disorders | |
IL192851A0 (en) | Compounds for the treatment of metabolic disorders | |
IL195392A0 (en) | Compounds for the treatment of metabolic disorders | |
IL187792A0 (en) | 4-anilino-3-quinolinecarbonitriles for the treatment of cancer | |
ZA200805522B (en) | Dioxoiane dérivates for the treatment of cancer | |
IL192982A0 (en) | Compounds for the treatment of metabolic disorders | |
GB0517386D0 (en) | Combinations for the treatment of cancer | |
TJ20050863A (en) | The way of narcotism treatment |